PaxMedica Valuation
Is PXMD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PXMD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PXMD *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PXMD *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PXMD *?
Key metric: As PXMD * is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is PXMD *'s PB Ratio? | |
|---|---|
| PB Ratio | -5.6x |
| Book | -US$536.92k |
| Market Cap | US$2.99m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does PXMD *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.1x | ||
LAB B Genomma Lab Internacional. de | 2.3x | 19.8% | Mex$24.8b |
RVV Revive Therapeutics | 0.6x | n/a | CA$4.2m |
ENVB Enveric Biosciences | 0.8x | n/a | US$3.3m |
RUA Rua Bioscience | 0.7x | n/a | NZ$4.7m |
PXMD * PaxMedica | n/a | -61.5% | Mex$3.0m |
Price-To-Book vs Peers: PXMD * has negative equity and a Price-To-Book Ratio (-5.6x) compared to the peer average (9.8x).
Price to Book Ratio vs Industry
How does PXMD *'s PB Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 77 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 77 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: PXMD * has negative equity and a Price-To-Book Ratio (-5.6x) compared to the Global Pharmaceuticals industry average (1.9x).
Price to Book Ratio vs Fair Ratio
What is PXMD *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -5.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate PXMD *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
ICON
US$17.6b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
n/a
IQVIA Holdings
US$36.5b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
0%
1Y
6.3%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%